Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators

Journal of Experimental Medicine

Volumn 212, Issue 2, 2015, Pages 129-137

  Flierl, Ulrike ^a,g   Nero, Tracy L ^a,b   Lim, Bock ^a   Arthur, Jane F ^c   Yao, Yu ^a   Jung, Stephanie M ^d   Gitz, Eelo ^e   Pollitt, Alice Y ^e   Zaldivia, Maria T K ^a   Jandrot Perrus, Martine ^f   Schäfer, Andreas ^g   Nieswandt, Bernhard ^h   Andrews, Robert K ^c   Parker, Michael W ^a,b   Gardiner, Elizabeth E ^c   Peter, Karlheinz ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f INSERM   (France)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTISENSE OLIGONUCLEOTIDE; C REACTIVE PROTEIN; COLLAGEN; FC RECEPTOR IIA; GLYCOPROTEIN VI; INTEGRIN; NUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 9; VON WILLEBRAND FACTOR; FIBRINOGEN RECEPTOR; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CELL SPREADING; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEGRADATION KINETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; MESENTERIC ARTERY; MESENTERIC VASCULAR OCCLUSION; METABOLISM; PATHOLOGY; PULMONARY EMBOLISM; RNA INTERFERENCE; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MESENTERIC ARTERIES; MESENTERIC VASCULAR OCCLUSION; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; PROTEIN BINDING; PULMONARY EMBOLISM; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84922754775     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20140391     Document Type: Article

References (29)

1. Advani, P.P., A. Paulus, A. Masood, T. Sher, and A. Chanan-Khan. 2011. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin. Drug Metab. Toxicol. 7:765-774. http://dx.doi.org/10.1517/17425255.2011.579105
2. Al-Tamimi, M., F.T. Mu, J.F. Arthur, Y. Shen, M. Moroi, M.C. Berndt, R.K. Andrews, and E.E. Gardiner. 2009. Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcγRIIa and induce GPVI ectodomain shedding. Platelets. 20:75-82. http://dx.doi.org/10.1080/09537100802645029
3. Arthur, J.F., J. Qiao, Y. Shen, A.K. Davis, E. Dunne, M.C. Berndt, E.E. Gardiner, and R.K. Andrews. 2012. ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and Syk-independent pathways. J. Thromb. Haemost. 10:1133-1141. http://dx.doi.org/10.1111/j.1538-7836.2012.04734.x
4. Chi, K.N., E. Eisenhauer, L. Fazli, E.C. Jones, S.L. Goldenberg, J. Powers, D. Tu, and M.E. Gleave. 2005. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 97:1287-1296. http://dx.doi.org/10.1093/jnci/dji252
5. Cognasse, F., H. Hamzeh, P. Chavarin, S. Acquart, C. Genin, and O. Garraud. 2005. Evidence of Toll-like receptor molecules on human platelets. Immunol. Cell Biol. 83:196-198. http://dx.doi.org/10.1111/j.1440-1711.2005.01314.x
6. Eckstein, F. 2000. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 10:117-121. http://dx.doi.org/10.1089/oli.1.2000.10.117
7. 2 single-chain antibodies as potential diagnostic tools and therapeutic agents. Blood. 109:3521-3528. http://dx.doi.org/10.1182/blood-2006-03-007179
8. Gibbins, J., J. Asselin, R. Farndale, M. Barnes, C.L. Law, and S.P. Watson. Tyrosine phosphorylation of the Fc receptor γ-chain in collagenstimulated platelets. J. Biol. Chem. 271:18095-18099. http://dx.doi.org/10.1074/jbc.271.30.18095
9. Gitz, E., A.Y. Pollitt, J.J. Gitz-Francois, O. Alshehri, J. Mori, S. Montague, G.B. Nash, M.R. Douglas, E.E. Gardiner, R.K. Andrews, et al. 2014. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood. 124:2262-2270. http://dx.doi.org/10.1182/blood-2014-05-572818
10. Grüner, S., M. Prostredna, M. Koch, Y. Miura, V. Schulte, S.M. Jung, M. Moroi, and B. Nieswandt. 2005. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood. 105:1492-1499. http://dx.doi.org/10.1182/blood-2004-06-2391
11. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature. 408:740-745. http://dx.doi.org/10.1038/35047123
12. Horii, K., M.L. Kahn, and A.B. Herr. 2006. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood. 108:936-942. http://dx.doi.org/10.1182/blood-2006-01-010215
13. Hu, H., P.C. Armstrong, E. Khalil, Y.C. Chen, A. Straub, M. Li, J. Soosairajah, C.E. Hagemeyer, N. Bassler, D. Huang, et al. 2011. GPVI and GPIbα mediate staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors. PLoS ONE. 6:e19190. http://dx.doi.org/10.1371/journal.pone.0019190
14. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995. http://dx.doi.org/10.1038/ni1112
15. Jung, S.M., M. Moroi, K. Soejima, T. Nakagaki, Y. Miura, M.C. Berndt, E.E. Gardiner, J.M. Howes, N. Pugh, D. Bihan, et al. 2012. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J. Biol. Chem. 287:30000-30013. http://dx.doi.org/10.1074/jbc.M112.359125
16. Krieg, A.M., A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:546-549. http://dx.doi.org/10.1038/374546a0
17. Krieg, A.M., P. Guga, and W. Stec. 2003. P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 13:491-499. http://dx.doi.org/10.1089/154545703322860807
18. Lennox, K.A., and M.A. Behlke. 2011. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 18:1111-1120. http://dx.doi.org/10.1038/gt.2011.100
19. Mangin, P.H., C. Tang, C. Bourdon, S. Loyau, M. Freund, B. Hechler, C. Gachet, and M. Jandrot-Perrus. 2012. A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. J. Pharmacol. Exp. Ther. 341:156-163. http://dx.doi.org/10.1124/jpet.111.189050
20. Marcucci, G., W. Stock, G. Dai, R.B. Klisovic, S. Liu, M.I. Klisovic, W. Blum, C. Kefauver, D.A. Sher, M. Green, et al. 2005. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 23:3404-3411. http://dx.doi.org/10.1200/JCO.2005.09.118
21. Massberg, S., M. Gawaz, S. Grüner, V. Schulte, I. Konrad, D. Zohlnhöfer, U. Heinzmann, and B. Nieswandt. 2003. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J. Exp. Med. 197:41-49. http://dx.doi.org/10.1084/jem.20020945
22. McKenzie, S.E., S.M. Taylor, P. Malladi, H. Yuhan, D.L. Cassel, P. Chien, E. Schwartz, A.D. Schreiber, S. Surrey, and M.P. Reilly. 1999. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J. Immunol. 162:4311-4318.
23. Nieswandt, B., and S.P. Watson. 2003. Platelet-collagen interaction: is GPVI the central receptor? Blood. 102:449-461. http://dx.doi.org/10.1182/blood-2002-12-3882
24. Ott, P.A., J. Chang, K. Madden, R. Kannan, C. Muren, C. Escano, X. Cheng, Y. Shao, S. Mendoza, A. Gandhi, et al. 2013. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother. Pharmacol. 71:183-191. http://dx.doi.org/10.1007/s00280-012-1995-7
25. Schwarz, M., P. Röttgen, Y. Takada, F. Le Gall, S. Knackmuss, N. Bassler, C. Büttner, M. Little, C. Bode, and K. Peter. 2004. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J. 18:1704-1706. http://dx.doi.org/10.1096/fj.04-1513fje
26. Semple, J.W., and J. Freedman. 2010. Platelets and innate immunity. Cell. Mol. Life Sci. 67:499-511. http://dx.doi.org/10.1007/s00018-009-0205-1
27. Tapp, L.D., E. Shantsila, B.J. Wrigley, B. Pamukcu, and G.Y. Lip. 2012. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J. Thromb. Haemost. 10:1231-1241. http://dx.doi.org/10.1111/j.1538-7836.2011.04603.x
28. van Rooij, E., and E.N. Olson. 2012. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11:860-872. http://dx.doi.org/10.1038/nrd3864
29. Wang, L., S. Chen, T. Xu, K. Taghizadeh, J.S. Wishnok, X. Zhou, D. You, Z. Deng, and P.C. Dedon. 2007. Phosphorothioation of DNA in bacteria by dnd genes. Nat. Chem. Biol. 3:709-710. http://dx.doi.org/10.1038/nchembio.2007.39